Kymera Therapeutics Inc (KYMR) Stock Price, Quote & News

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in a...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 5300

Website: www.kymeratx.com

Address:

500 North Beacon Street, 4th Floor, Watertown, United States

BillionerOfKing Feb. 12 at 6:46 PM

$KYMR Current Stock Price: $84.63 Contracts to trade: $85.0 KYMR Feb 20 2026 Call Entry: $1.70 Exit: $2.22 ROI: 31% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

cheruskian Feb. 12 at 9:25 AM

$KYMR I'm writing both ways options at this level.

0 · Reply

SuperGreenToday Feb. 10 at 8:09 PM

$KYMR Share Price: $79.44 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.93 – $6.09 Target Zone: $9.16 – $11.20 Potential Upside: 76% ROI Time to Expiration: 191 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Feb. 10 at 5:21 PM

William Blair⬆️ $NKTR to Outperform and provided its Take and Stock Thoughts. $CRVS $REGN - SNY $APGE $KYMR William Blair said: Rezpeg, continues to demonstrate deepening of response and durability with longer-term data—Re: durability, WB noted, there appears to be no meaningful deterioration of response when comparing the monthly dosing to the quarterly dosing—noted, there were no reported cases of conjunctivitis, erythema, oral ulcers, cardiovascular adverse events, or malignancies in the Phase 2 REZOLVE-AD study of rezpeg. Here's what else William Blair had to say: https://x.com/Quantumup1/status/2021272497862115591?s=20

0 · Reply

stu4 Feb. 9 at 9:19 PM

$CADL …blah blah…immunology has been going on for years …this company is years behind others especially in prostate cancer , therapies exist !!! DAH ….and are working The rest of the BS here is hype , or this would be at $79 along with $KYMR , or $ARWR ….but instead is running a close 2nd behind $IMNN , hahaha

2 · Reply

SuperGreenToday Feb. 2 at 1:14 PM

$KYMR Share Price: $72.73 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.74 – $5.86 Target Zone: $8.78 – $10.73 Potential Upside: 75% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

cheruskian Feb. 1 at 9:29 AM

$KYMR the way the market is trading biotech these days we are probably going to see the 60s again here.

0 · Reply

ZacksResearch Jan. 30 at 4:01 PM

$KYMR surges 68.9% in 6 months — what's driving the rally? The phase IIb BREADTH study for KT-621 in eosinophilic asthma marks a key step forward for developing oral treatments for type II inflammatory diseases, with top-line data expected in late 2027. Plus, KYMR holds a Zacks Rank #2 (Buy), signaling strong potential. See what makes the investment case strong for Kymera here 👉 https://www.zacks.com/stock/news/2826252/kymr-initiates-dosing-in-mid-stage-asthma-study-of-lead-candidate?cid=sm-stocktwits-2-2826252-body-31192&ADID=SYND_STOCKTWITS_TWEET_2_2826252_BODY_31192

0 · Reply

ZacksResearch Jan. 30 at 2:18 PM

$KYMR just hit a key clinical milestone — this is one to watch Kymera Therapeutics has initiated phase IIb dosing of its oral lead candidate KT-621 in eosinophilic asthma, targeting STAT6, with top-line BREADTH study data expected in late 2027. Progress like this keeps the pipeline narrative alive. See the full study details here 👉 https://www.zacks.com/stock/news/2826252/kymr-initiates-dosing-in-mid-stage-asthma-study-of-lead-candidate?cid=sm-stocktwits-2-2826252-teaser-31162&ADID=SYND_STOCKTWITS_TWEET_2_2826252_TEASER_31162

0 · Reply

SuperGreenToday Jan. 30 at 12:50 PM

$KYMR Share Price: $73.91 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.74 – $5.86 Target Zone: $8.79 – $10.75 Potential Upside: 75% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 7:00 AM EST - 5 weeks ago

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Dec 11, 2025, 4:01 PM EST - 2 months ago

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 8, 2025, 4:01 PM EST - 2 months ago

Kymera Therapeutics Announces Proposed Public Offering

Dec 8, 2025, 3:50 PM EST - 2 months ago

This Drugmaker's Stock Is Soaring Over 40% Monday

Dec 8, 2025, 3:47 PM EST - 2 months ago

Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript

Dec 8, 2025, 9:15 AM EST - 2 months ago

Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum

Dec 8, 2025, 7:42 AM EST - 2 months ago

Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug.

Dec 8, 2025, 7:00 AM EST - 2 months ago

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

Dec 5, 2025, 4:01 PM EST - 2 months ago

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Dec 3, 2025, 1:43 PM EST - 2 months ago

Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 25, 2025, 7:00 AM EST - 3 months ago

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Nov 24, 2025, 7:00 AM EST - 3 months ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Nov 10, 2025, 3:31 PM EST - 3 months ago

Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 4, 2025, 4:26 PM EST - 3 months ago

Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 7:00 AM EST - 3 months ago

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Oct 28, 2025, 7:00 AM EDT - 4 months ago

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Sep 9, 2025, 4:42 PM EDT - 5 months ago

Kymera Therapeutics, Inc. (KYMR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 1:31 PM EDT - 6 months ago

Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript

Sep 3, 2025, 7:00 AM EDT - 6 months ago

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

Aug 27, 2025, 7:00 AM EDT - 6 months ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Aug 12, 2025, 9:47 AM EDT - 6 months ago

The Best Small-Cap Stocks to Buy Now

DNLI WAY

Aug 11, 2025, 1:25 PM EDT - 6 months ago

Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 6 months ago

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Jun 26, 2025, 11:56 PM EDT - 8 months ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Jun 25, 2025, 9:15 AM EDT - 8 months ago

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

GILD

Jun 25, 2025, 7:05 AM EDT - 8 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:00 AM EDT - 8 months ago

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

GILD

Jun 5, 2025, 4:16 PM EDT - 9 months ago

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial

Jun 2, 2025, 2:55 PM EDT - 9 months ago

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Jun 2, 2025, 7:44 AM EDT - 9 months ago

Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.

Jun 2, 2025, 7:00 AM EDT - 9 months ago

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

May 30, 2025, 4:01 PM EDT - 9 months ago

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

May 29, 2025, 7:00 AM EDT - 9 months ago

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

May 19, 2025, 12:15 PM EDT - 9 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

May 14, 2025, 4:59 PM EDT - 10 months ago

Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff

May 9, 2025, 9:37 PM EDT - 10 months ago

Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:01 AM EDT - 10 months ago

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

May 9, 2025, 7:00 AM EDT - 10 months ago

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

May 7, 2025, 7:00 AM EDT - 10 months ago

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

Apr 22, 2025, 7:00 AM EDT - 10 months ago

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Apr 9, 2025, 7:00 AM EDT - 11 months ago

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

Feb 27, 2025, 2:48 PM EST - 1 year ago

Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Jan 30, 2025, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Jan 14, 2025, 7:00 AM EST - 1 year ago

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Jan 7, 2025, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Dec 7, 2024, 1:07 AM EST - 1 year ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Nov 3, 2024, 4:11 PM EST - 1 year ago

Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript

BillionerOfKing Feb. 12 at 6:46 PM

0 · Reply

cheruskian Feb. 12 at 9:25 AM

$KYMR I'm writing both ways options at this level.

0 · Reply

SuperGreenToday Feb. 10 at 8:09 PM

0 · Reply

Quantumup Feb. 10 at 5:21 PM

0 · Reply

stu4 Feb. 9 at 9:19 PM

2 · Reply

SuperGreenToday Feb. 2 at 1:14 PM

0 · Reply

cheruskian Feb. 1 at 9:29 AM

$KYMR the way the market is trading biotech these days we are probably going to see the 60s again here.

0 · Reply

ZacksResearch Jan. 30 at 4:01 PM

0 · Reply

ZacksResearch Jan. 30 at 2:18 PM

0 · Reply

SuperGreenToday Jan. 30 at 12:50 PM

0 · Reply

MikeyNJ Jan. 28 at 3:08 PM

$KYMR Barclay's raises price target from $119 to $133. Amazing!

0 · Reply

MooseG Jan. 27 at 12:33 PM

$KYMR this looks dead for awhile.

1 · Reply

JFais Jan. 23 at 8:39 PM

Better stated: $APGE- we've seen a good number of + biotech binaries lately, perhaps due for a significant (downward) revaluation here? 4x avg volume so far on the high side, but certainly far from panic levels (as of yet) Also, atopic dermatitis very crowded & while the pie is very large, it's limited as well (yes, it can be both) New drugs shining like $CRVS ITK will be at the expense of other potential entrants like $APGE or $KYMR IMO

0 · Reply

JFais Jan. 21 at 2:14 PM

$CRVS- updated EV gap vs $KYMR $APGE $NKTR

2 · Reply

cheruskian Jan. 21 at 7:23 AM

I'm genuinely curious about the reason behind those $KYMR buyout speculations. They have enough cash in the bank to get at least two wholly owned assets through phase 3 trials without limiting their research operations. They could become the next$REGN Why would they sell out now, or anytime soon?

1 · Reply

JuggernautRaider Jan. 18 at 9:18 PM

$ALT where was it discovered that the lean mass preserving weight loss in pemvi’s trials wasn’t caused by it? Even the placebo arm didn’t show it, although it outperformed all historical norms. @BioRich here are three biotech gems. Check them out - it’s more fun to be positive on stocks than a Negative Nancy. LMK what you think about $TLSA $KYMR and $IXHL are all very intriguing to me (KYMR to hold for a buyout, TLSA & IXHL to hold long like CCCC or IMRX). Thoughts on these other ones? We can formally agree to disagree on AltImmune. I am a bull 🐂 and you are a 🐻 we all get it 🚀

2 · Reply

JFais Jan. 17 at 1:48 PM

Per your request: EV gap for $CRVS vs $KYMR $APGE $NKTR All in atopic dermatitis space, though obviously far from being apples to apples (more like apples to fruit loops). Still fun re point of comparison

1 · Reply

MooseG Jan. 16 at 8:26 PM

$KYMR at close to pre-trial data news levels. Didnt see that coming.

2 · Reply

ZacksResearch Jan. 5 at 8:20 PM

$KYMR surged 82.4% over the past year — what's driving this biotech rocket? 🚀 ✅ Positive phase Ib BroADen study results for KT-621 in eczema ✅ FDA's Fast Track designation boosts prospects 🚀 Outperforming industry, sector & S&P 500 See why current investors might want to hold on here 👉 https://www.zacks.com/stock/news/2812002/kymr-skyrockets-824-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2812002-body-27426&ADID=SYND_STOCKTWITS_TWEET_2_2812002_BODY_27426

0 · Reply

ZacksResearch Jan. 5 at 7:20 PM

$KYMR up 82.4% in a year — and biotech bulls are eyeing what comes next 👀 The rally follows strong phase Ib BroADen data for KT-621 and FDA Fast Track designation for atopic dermatitis, a combo that put Kymera firmly on investors’ radar. Is there more upside potential into 2026? Full breakdown here 👉 https://www.zacks.com/stock/news/2812002/kymr-skyrockets-824-in-a-year-more-upside-potential-in-2026?cid=sm-stocktwits-2-2812002-teaser-27425&ADID=SYND_STOCKTWITS_TWEET_2_2812002_TEASER_27425

0 · Reply

MikeyNJ Jan. 5 at 6:38 PM

$KYMR filled most of that big gap up. 23 analysts cover KYMR with average 12 month target of $117. Looks like a pretty good entry point.

1 · Reply

frenulum1 Jan. 2 at 8:40 PM

$KYMR sell the news.. textbook biotech play

0 · Reply

Market Cap	6.10B
Revenue (ttm)	47.07M
Net Income (ttm)	-223.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-475.59%
Debt to Equity Ratio	0.00

Volume	557,663
Avg Vol	1,048,184
Day's Range	N/A - N/A
Shares Out	71.95M
Stochastic %K	77%
Beta	2.21
Analysts	Strong Sell
Price Target	$116.71